Oligonucleotides and methods for detecting Borrelia burgdorferi
AssigneeQuest Diagnostics Investments Incorporated
InventorsMaurice Exner, Hasnah Hamdan, Michael Lewinski
Life of this patent
Estimating the term…
Abstract
The present invention provides methods and compositions for determining the presence and/or amount of Borrelia burgdorferi nucleic acids in a test sample related to Lyme disease. In particular, substantially purified oligonucleotide primers and probes are described that can be used for qualitatively and quantitatively detecting Borrelia burgdorferi nucleic acid in a test sample by amplification methods. The present invention also provides primers and probes for generating and detecting control nucleic acid sequences that provide a convenient method for assessing internal quality control of the Borrelia burgdorferi assay.
Claims1
A method for producing an oligonucleotide that is a hybrid of human placental DNA with FlaA nucleic acid sequence, comprising:
- amplifying human placental DNA using a pair of oligonucleotide primers having the sequences set forth in SEQ ID NO:4 and SEQ ID NO:5, wherein said primers each further contain a terminal FlaA nucleic acid sequence comprising 5 or more contiguous nucleotides selected from 5′-TTG CAA ATC TTT TCT CTG GTG-3′ (SEQ ID NO:1) or 5′-AGA ATT AAC TCC GCC TTG AGA-3′ (SEQ ID NO:2) to provide a plurality of human placental-FlaA nucleic acid hybrid amplicons;
- and
- purifyng the human placental-FlaA nucleic acid hybrid amplicons.
Dependencies are inferred from the claim text.